GlassScriptPhysician profile
Julie Green Grinstead
NPI 1376635177
$1,335.36
in general payments reported to CMS, 2019-2025
26 companies · $490 in 2025
The $490 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $13.99 · 2021: $289 · 2022: $109 · 2023: $145 · 2024: $117 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $153.35 | 2024-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $141.98 | 2019-2023 | |
| Daiichi Sankyo INC. | $131.30 | 2024-2025 | Injectafer |
| Aspira Women'S Health INC | $128.28 | 2021 | |
| Mayne Pharma Commercial LLC | $97.39 | 2024-2025 | |
| Pfizer INC. | $80.37 | 2019-2023 | |
| Coopersurgical, INC. | $77.88 | 2019-2023 | Mara Console |
| Organon LLC | $58.89 | 2022-2025 | Jada System |
| Exeltis, USA INC. | $54.93 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $48.52 | 2022-2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Sage Therapeutics, LLC | $41.08 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $40.38 | 2021-2022 | |
| Shield Therapeutics INC | $38.51 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $37.26 | 2025 | |
| Evofem Biosciences, INC. | $26.54 | 2025 | Solosec, Phexx, Phexxi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $25.80 | 2022-2023 | |
| Duchesnay USA Incorporated | $19.07 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.70 | 2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.26 | 2019 | |
| Astellas Pharma US INC | $15.54 | 2021 | |
| Becton, Dickinson and Company | $14.77 | 2023 | Bd Onclarity |
| Pacira Pharmaceuticals Incorporated | $14.68 | 2021 | |
| Eisai INC. | $13.99 | 2020 | |
| Amgen INC. | $13.89 | 2021 | |
| Avion Pharmaceuticals | $13.21 | 2019 | |
| Smith+Nephew, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Grinstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.